查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566884

老齡化黃斑部病變市場：按藥物類型、疾病類型和分銷管道分類：2024-2033 年全球機會分析和產業預測

Age Related Macular Degeneration Market By Drug Type , By Disease Type (Wet Age Related Macular Degeneration , Dry Age Related Macular Degeneration ) By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

老齡化黃斑部病變市場

2023年，老齡化黃斑部病變市場價值為100億美元，預計2024年至2033年複合年成長率為5%，到2033年達到162億美元。

老齡化黃斑部病變是一種視力障礙，會導致視網膜中央部分（稱為黃斑部）劣化。它開始時視力輕微模糊，最終導致中心視力喪失。這種疾病有兩類：乾性（萎縮性）和濕性（新生血管性）。在乾性黃斑部病變中，黃斑逐漸變薄，而在濕性黃斑部病變，視網膜下的血管異常生長。

老化人口的指數級成長和盛行率的上升是老齡化黃斑部病變市場的主要驅動力。此外，診斷技術的進步促進了疾病的早期發現和及時治療，支持了市場開拓。最近，人工智慧和深度學習徹底改變了老齡化黃斑部病變的診斷和治療模式。該技術有助於準確檢測眼部狀況並評估疾病進展的風險。

然而，當疾病處於高度晚期時，治療方法效果有限，限制了老齡化黃斑部病變市場的成長。此外，購買治療該疾病的基本藥物（例如抗血管內皮生長因子注射液）的費用高昂，使部分患者無法接受治療。這是市場開拓的障礙。英國科學期刊出版商 BioMed Central 發表的一篇論文稱，與老齡化的黃斑部病變是導致視力喪失的主要原因之一，預計到 2040 年將影響 2.88 億人。

按部門審查

老齡化黃斑部病變市場分為藥物類型、疾病類型、通路和區域。依藥物類型分為阿柏西普、雷珠單抗等。依疾病類型分為濕性老齡化黃斑部病變（AMD）和乾性老齡化黃斑部病變（AMD）。依銷售管道分為醫院藥局、零售藥局、網路藥局。從區域來看，分析包括北美、歐洲、亞太地區和拉丁美洲地區。

主要發現

從藥物類型來看，阿柏西普在老齡化黃斑部病變病變市場中佔據主導地位。

依疾病類型分類，濕性老齡化黃斑部病變（AMD）細分市場佔有重要佔有率。

從銷售管道來看，醫院藥局板塊處於市場領先地位。

從地區來看，北美市場呈現強勁成長動能。

該報告可以客製化。

  • 監管指引
  • 新增根據客戶興趣客製化的公司簡介
  • 公司簡介的擴充列表
  • 歷史市場資料

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 主要投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

老齡化黃斑部病變市場：依藥物類型

  • 市場概況
  • 阿柏西普
  • 雷珠單抗
  • 其他

老齡化黃斑部病變市場：依疾病類型

  • 市場概況
  • 濕性老齡化黃斑部病變（AMD）
  • 乾性老齡化黃斑部病變（AMD）

第6章老齡化黃斑部病變市場：按分銷管道

  • 市場概況
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章市場概述老齡化黃斑部病變市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國老齡化黃斑部病變市場
    • 加拿大老齡化黃斑部病變市場
    • 墨西哥老齡化黃斑部病變市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國老齡化黃斑部病變市場
    • 德國老齡化黃斑部病變市場
    • 義大利老齡化黃斑部病變市場
    • 西班牙老齡化黃斑部病變市場
    • 英國老齡化黃斑部病變市場
    • 其他歐洲國家老齡化黃斑部病變市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國老齡化黃斑部病變市場
    • 日本老齡化黃斑部病變市場
    • 印度老齡化黃斑部病變市場
    • 韓國老齡化黃斑部病變市場
    • 澳洲老齡化黃斑部病變市場
    • 其他亞太地區老齡化黃斑部病變市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西老齡化黃斑部病變市場
    • 南非老齡化黃斑部病變市場
    • 沙烏地老齡化黃斑部病變市場
    • 其他拉丁美洲/中東/非洲老齡化黃斑部病變市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Biogen
  • Bayer AG
  • Coherus Biosciences Inc
  • Sanofi
  • Apellis Pharmaceuticals
  • Bausch Health Companies Inc.
  • Ionis Pharmaceuticals, Inc
簡介目錄
Product Code: A201849

Age Related Macular Degeneration Market

The age related macular degeneration market was valued at $10.0 billion in 2023 and is projected to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Age related macular degeneration is a visual impairment in which the central portion of the retina, known as macula, deteriorates. Beginning with slight blurred vision, the disease eventually leads to loss of central eyesight. There are two categories of the disease: dry (atrophic) and wet (neovascular). Gradual thinning of the macula occurs in dry macular degeneration, whereas wet macular degeneration happens due to abnormal growth of blood vessels under the retina.

Exponential increase in the aging population and rise in prevalence of the disease are the key drivers of the age related macular degeneration market. In addition, advancements in diagnostic techniques are leading to early detection and timely treatment of the disease, thereby augmenting the market development. In recent times, AI and deep learning are revolutionizing the landscape of age related macular degeneration diagnosis and treatment. The technology helps in precise detection of the eye condition and assesses the risk pertaining to the progression of the disease to advanced stages.

However, in case of disease advancement to high stages, treatment procedures exhibit limited to no efficacy, thereby restraining the growth of the age related macular degeneration market. Moreover, the high expense of purchasing medications essential for curing the disease, such as anti-vascular endothelial growth factor injections, constraints several patients from undergoing the treatment. This hampers the development of the market. According to an article published by the UK-based scientific journals publisher-BioMed Central- age related macular degeneration is one of the leading causes of vision loss and by 2040, the disease is anticipated to impact 288 million individuals.

Segment Review

The age related macular degeneration market is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into aflibercept, ranibizumab, and others. Depending on disease type, it is bifurcated into wet age related macular degeneration (AMD) and dry age related macular degeneration (AMD). As per distribution channel, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug type, the aflibercept segment dominates the age related macular degeneration market.

Depending on disease type, the wet age-related macular degeneration (AMD) segment acquires a significant share of the market.

As per distribution channel, the hospital pharmacy segment leads in the market.

Region wise, the market exhibits robust growth in North America.

Competition Analysis

The leading players operating in the global age related macular degeneration market include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Biogen, Bayer AG, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals, Bausch Health Companies Inc., and Ionis Pharmaceuticals, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Drug Type

  • Aflibercept
  • Ranibizumab
  • Others

By Disease Type

  • Wet Age Related Macular Degeneration (AMD)
  • Dry Age Related Macular Degeneration (AMD)

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Regeneron Pharmaceuticals Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Bayer AG
    • Coherus Biosciences Inc
    • Sanofi
    • Apellis Pharmaceuticals
    • Bausch Health Companies Inc.
    • Ionis Pharmaceuticals, Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Type
  • 4.2. Aflibercept
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Ranibizumab
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Disease Type
  • 5.2. Wet Age Related Macular Degeneration (AMD)
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Dry Age Related Macular Degeneration (AMD)
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacy
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail Pharmacy
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacy
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: AGE RELATED MACULAR DEGENERATION MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Drug Type
    • 7.2.3. Market Size and Forecast, By Disease Type
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Age Related Macular Degeneration Market
      • 7.2.6.1. Market Size and Forecast, By Drug Type
      • 7.2.6.2. Market Size and Forecast, By Disease Type
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Age Related Macular Degeneration Market
      • 7.2.7.1. Market Size and Forecast, By Drug Type
      • 7.2.7.2. Market Size and Forecast, By Disease Type
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Age Related Macular Degeneration Market
      • 7.2.8.1. Market Size and Forecast, By Drug Type
      • 7.2.8.2. Market Size and Forecast, By Disease Type
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Drug Type
    • 7.3.3. Market Size and Forecast, By Disease Type
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Age Related Macular Degeneration Market
      • 7.3.6.1. Market Size and Forecast, By Drug Type
      • 7.3.6.2. Market Size and Forecast, By Disease Type
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Age Related Macular Degeneration Market
      • 7.3.7.1. Market Size and Forecast, By Drug Type
      • 7.3.7.2. Market Size and Forecast, By Disease Type
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Age Related Macular Degeneration Market
      • 7.3.8.1. Market Size and Forecast, By Drug Type
      • 7.3.8.2. Market Size and Forecast, By Disease Type
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Age Related Macular Degeneration Market
      • 7.3.9.1. Market Size and Forecast, By Drug Type
      • 7.3.9.2. Market Size and Forecast, By Disease Type
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Age Related Macular Degeneration Market
      • 7.3.10.1. Market Size and Forecast, By Drug Type
      • 7.3.10.2. Market Size and Forecast, By Disease Type
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Age Related Macular Degeneration Market
      • 7.3.11.1. Market Size and Forecast, By Drug Type
      • 7.3.11.2. Market Size and Forecast, By Disease Type
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Drug Type
    • 7.4.3. Market Size and Forecast, By Disease Type
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Age Related Macular Degeneration Market
      • 7.4.6.1. Market Size and Forecast, By Drug Type
      • 7.4.6.2. Market Size and Forecast, By Disease Type
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Age Related Macular Degeneration Market
      • 7.4.7.1. Market Size and Forecast, By Drug Type
      • 7.4.7.2. Market Size and Forecast, By Disease Type
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Age Related Macular Degeneration Market
      • 7.4.8.1. Market Size and Forecast, By Drug Type
      • 7.4.8.2. Market Size and Forecast, By Disease Type
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Age Related Macular Degeneration Market
      • 7.4.9.1. Market Size and Forecast, By Drug Type
      • 7.4.9.2. Market Size and Forecast, By Disease Type
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Age Related Macular Degeneration Market
      • 7.4.10.1. Market Size and Forecast, By Drug Type
      • 7.4.10.2. Market Size and Forecast, By Disease Type
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Age Related Macular Degeneration Market
      • 7.4.11.1. Market Size and Forecast, By Drug Type
      • 7.4.11.2. Market Size and Forecast, By Disease Type
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Drug Type
    • 7.5.3. Market Size and Forecast, By Disease Type
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Age Related Macular Degeneration Market
      • 7.5.6.1. Market Size and Forecast, By Drug Type
      • 7.5.6.2. Market Size and Forecast, By Disease Type
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Age Related Macular Degeneration Market
      • 7.5.7.1. Market Size and Forecast, By Drug Type
      • 7.5.7.2. Market Size and Forecast, By Disease Type
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Age Related Macular Degeneration Market
      • 7.5.8.1. Market Size and Forecast, By Drug Type
      • 7.5.8.2. Market Size and Forecast, By Disease Type
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Age Related Macular Degeneration Market
      • 7.5.9.1. Market Size and Forecast, By Drug Type
      • 7.5.9.2. Market Size and Forecast, By Disease Type
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Regeneron Pharmaceuticals Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Biogen
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Bayer AG
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Coherus Biosciences Inc
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Sanofi
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Apellis Pharmaceuticals
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Bausch Health Companies Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Ionis Pharmaceuticals, Inc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments